FidoCure
FidoCure, operated by One Health Company, is a Palo Alto-based veterinary health technology company that applies AI-driven precision medicine and DNA sequencing to deliver personalized targeted therapies for canine cancer, serving pet parents and 1,300+ veterinary clinics across 32 US states.
- Company typePrivate
- Founded2018
- HeadquartersPalo Alto, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What FidoCure does
FidoCure, operated by One Health Company, Inc. and headquartered in Palo Alto, California, is a veterinary health technology company that applies AI-driven precision medicine to canine cancer. Its core product combines DNA sequencing of canine tumor tissue at a CLIA-certified laboratory with machine learning analysis of the largest proprietary canine cancer clinico-genomic dataset in the world (2 billion data points from thousands of sequenced and longitudinally followed dogs) to identify cancer-driving mutations and recommend targeted therapies matched to each dog's tumor profile. A streamlined Therapy Only Service provides expedited access to targeted therapies for cancers with known biomarkers (c-Kit-driven mast cell tumors, BRAF+ transitional cell carcinoma), and veterinarians access results and clinical guidance through a dedicated DVM portal (dvm.fidocure.com) with telemedicine support from the company's medical affairs team.
The company serves three primary stakeholders: pet parents seeking treatment options beyond standard chemotherapy and radiation for dogs with cancer, veterinarians and veterinary oncologists seeking advanced precision-medicine tools to differentiate their practice, and (secondarily) human biopharmaceutical companies that use FidoCure's comparative oncology dataset for drug R&D, biomarker discovery, and clinical-trial proof-of-concept studies. To date, FidoCure has guided treatment for over 6,000 dogs and works with 1,300+ veterinary clinics and oncology specialists across 32 US states. Targeted therapies are dispensed through partner compounding pharmacies that ship within 3–5 business days, leveraging AMDUCA to legally repurpose FDA-approved human drugs for extra-label canine use.
FidoCure generates revenue primarily by invoicing veterinarians for the one-time DNA sequencing diagnostic and by facilitating transactions for targeted therapies through partner compounding pharmacies (typically billed separately). Pricing is not publicly disclosed and varies by clinic; the service is covered by most pet insurance companies. GTM combines direct field engagement by a veterinary affairs team with a self-serve DVM portal and content-led adoption via case studies, webinars, and peer-reviewed publications. The company is VC-backed (a16z, Y Combinator, Polaris Partners, Lerer Hippeau, Tau Ventures, and others) and has published multiple studies in Nature-family journals, including a 2025 Nature Scientific Reports paper demonstrating up to a 50% reduction in risk of death for hemangiosarcoma patients treated with the precision medicine approach.
FidoCure firmographics
Firmographics- Name
- FidoCure
- Legal name
- One Health Company, Inc.
- Website
- https://fidocure.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- FidoCure, operated by One Health Company, is a Palo Alto-based veterinary health technology company that applies AI-driven precision medicine and DNA sequencing to deliver personalized targeted therapies for canine cancer, serving pet parents and 1,300+ veterinary clinics across 32 US states.
- Ownership category
- akta.pro rank
FidoCure industry classification
Industry- Product category
- Veterinary Precision Oncology
- NAICS
- Medical Laboratories (621511), Veterinary Services (541940), In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071), Services-Prepackaged Software (7372)
- akta.pro primary industry
- Molecular & Genetic Testing (Breed, Hereditary Disease, Oncology) (HLAMADAE)
- akta.pro secondary industries
- Oncology Diagnostics (Liquid/Tissue Biomarkers, Flow Cytometry) (HLAMADAJ), Tele-veterinary & Virtual Care Platforms (Video/Chat, Remote Triage) (HLAMAGAB), Molecular Diagnostics (PCR/qPCR, NGS-based assays) (HLAAALAA)
Keywords
Where FidoCure is headquartered
LocationHeadquarters
- HQ city
- Palo Alto
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
FidoCure business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- DNA Sequencing Diagnostic Testing: FidoCure invoices veterinarians for genomic testing services. Tissue samples are submitted for DNA sequencing at a CLIA certified lab, generating a personalized DNA report identifying genetic mutations.
- Targeted Therapy Access Facilitation: FidoCure facilitates access to FDA-approved human targeted therapies through a network of partner compounding pharmacies. The company enables veterinarians to prescribe and order therapies based on genetic test results. FidoCure does not directly supply drugs but connects pet parents with pharmacy partners.
- Therapy Only Service: For certain cancers like mast cell tumors (c-Kit driven) and transitional cell carcinomas (BRAF+), veterinarians can receive expedited access to specific targeted therapies without full genomic sequencing.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Pay-as-you-go | DNA Sequencing Diagnostic |
| Other | Pay-as-you-go | Targeted Therapy Access |
Go-to-market motion3 records
Distribution channels3 records
Marketing channels7 records
FidoCure product offering
Product offeringCore offering
FidoCure, developed by One Health Company, provides genomic DNA sequencing of canine tumor tissue at a CLIA-certified laboratory to identify cancer-driving mutations, then recommends FDA-approved targeted therapies that veterinarians can prescribe. The service combines genomic testing with tumor profiling and AI-driven therapeutic matching, and includes telemedicine-enabled clinical guidance for prescribing veterinarians and facilitated access to compounded targeted therapies through partner pharmacies.
Product overview
FidoCure is a comprehensive canine cancer care service developed by One Health Company that provides genomic testing and personalized targeted therapy recommendations for dogs with cancer. The core offering consists of DNA Sequencing & Targeted Therapy, which sequences tumor DNA at CLIA-certified labs to identify mutations and recommend targeted treatments. An optional Therapy Only Service provides expedited access for known biomarker-driven cancers like mast cell tumors and transitional cell carcinoma. Veterinarians access results and manage patients through a dedicated Veterinary Portal with telemedicine support. The platform is powered by AI and real-world evidence from the largest canine cancer clinico-genomic dataset in the world, enabling personalized treatment recommendations beyond traditional chemotherapy and radiation.
Differentiator
Problem solved
Functional benefit
Products and services
- FidoCure DNA Sequencing & Targeted Therapy A comprehensive genomic testing service for canine cancer that sequences tumor DNA at a CLIA-certified laboratory, generates a personalized DNA report identifying cancer-driving mutations, and recommends targeted therapies for veterinarians to prescribe. It is offered to veterinary clinics and oncology specialists who bill pet parents.
- FidoCure Therapy Only Service A standalone service for cases such as mast cell tumors (c-Kit driven) and transitional cell carcinoma (BRAF+) that provides expedited data-based reports and therapy access without full genomic sequencing, leveraging known biomarkers to enable faster targeted therapy initiation.
Quantifiable outcome
- Dogs with hemangiosarcoma may experience up to 50% reduced risk of death using precision medicine approach
- +3 more outcomes
Companies that use FidoCure
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles2 records
FidoCure technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature4 records
FidoCure partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core.
- Fetch AIcorePartnership for analyzing and confirming the real-world effectiveness of FidoCure's precision medicine approach using AI technology at scale.
- EisaicoreOne Health canine data helped Eisai drug reach Phase 2 at Mass General Hospital, demonstrating the value of canine comparative oncology for human drug development.
- Stanford UniversitycoreAcademic collaboration on peer-reviewed research in canine cancer genomics and precision medicine.
- Broad Institute of MIT and HarvardcoreResearch collaboration on genomic alterations in canine cancer, particularly hemangiosarcoma studies.
- Tufts UniversitycoreCollaborative research on precision medicine tools for understanding hemangiosarcoma in dogs.
- University of Georgia College of Veterinary MedicinecoreAcademic partnership for advancing canine cancer research and treatment outcomes.
- Partner Compounding PharmaciescoreLicensed and Board of Pharmacy inspected facilities preparing targeted therapies from human-grade APIs sourced from FDA-registered repackagers. Therapies are compounded and shipped within 3-5 business days.
Scale indicators5 records
Recent moves6 records
Expansion highlights5 records
FidoCure competitors and assessment
Company assessmentBroad incumbents
- Antech Diagnostics (Mars Petcare): Antech is the second-largest veterinary reference lab network in North America, owned by Mars Petcare, and operates adjacent pet genetics and wellness screening products. It competes indirectly via clinic-level diagnostics bundling.
- IDEXX Laboratories: IDEXX is the dominant veterinary diagnostics company with broad reference lab, in-clinic analyzer, and software offerings, and now owns PetDx. It is the most likely well-capitalized incumbent to bundle canine genomic oncology into its clinic stack.
- Zoetis: Zoetis is the largest global animal health company, spanning pharma, diagnostics, and genetics (via its acquisition of Basepaws and Wisdom Panel). It represents the broadest incumbent threat across FidoCure's verticals.
- Wisdom Panel (Mars Petcare): Wisdom Panel is the leading direct-to-consumer dog breed and health genetics test, owned by Mars Petcare. It is comparable as a canine genomics consumer brand, though its clinical oncology depth is shallow relative to FidoCure.
Emerging players
- Embark Veterinary: Embark offers direct-to-consumer dog DNA testing for breed, traits, and health risks. It overlaps with FidoCure on the canine genomics infrastructure but serves consumer breed/health screening rather than oncology therapeutic matching.
Direct peers
- PetDx: PetDx (now part of IDEXX) developed a liquid biopsy test (OncoK9) for early cancer detection in dogs using next-generation sequencing. It is the most direct competitor in canine genomic oncology diagnostics, although FidoCure focuses on therapeutic matching rather than screening.
- Anivive Lifesciences: Anivive is a veterinary pharma and biotech company developing novel therapeutics for companion animal cancers and infectious diseases. It overlaps with FidoCure on the canine oncology drug-access value chain.
- Torigen Pharmaceuticals: Torigen develops autologous cancer immunotherapies (Versinia) for companion animals, sold directly to veterinary clinics. It competes for the same veterinary oncology dollar via a different therapeutic modality.
- VetDC (now Elanco): VetDC developed Tanovea, a novel chemotherapy for canine lymphoma, and was acquired by Elanco. It is a direct comparator in the canine oncology therapeutics space that FidoCure occupies.
- Ardent Animal Health: Ardent Animal Health provides advanced veterinary specialty services including oncology, internal medicine, and surgery across multiple clinics. It represents an alternate channel through which canine oncology demand is currently served.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
FidoCure social profiles
Digital presenceFidoCure compliance and trust
Trust signalCompliance3 records
FidoCure financial estimates
Financial estimateRevenue estimate
Valuation estimate
FidoCure leadership team
Management profileNumber of profiles
Profiles9 records
FidoCure funding detail
Funding detailFunding overview
Funding rounds7 records
Investors17 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
FidoCure M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about FidoCure
What does FidoCure do?
FidoCure, developed by One Health Company, provides genomic DNA sequencing of canine tumor tissue at a CLIA-certified laboratory to identify cancer-driving mutations, then recommends FDA-approved targeted therapies that veterinarians can prescribe. The service combines genomic testing with tumor profiling and AI-driven therapeutic matching, and includes telemedicine-enabled clinical guidance for prescribing veterinarians and facilitated access to compounded targeted therapies through partner pharmacies.
Is FidoCure a public or private company?
FidoCure is a private company. It is classified as venture growth investor backed and is currently operating.
When was FidoCure founded?
FidoCure was founded in 2018. It employs 11 to 50 people.
Where is FidoCure based?
FidoCure is headquartered in Palo Alto, United States, in the North America region.
How does FidoCure make money?
Three revenue lines are on record. DNA Sequencing Diagnostic Testing is the primary driver. The others are targeted Therapy Access Facilitation and therapy Only Service.
Who are FidoCure's main competitors?
Broad incumbents on record are Antech Diagnostics (Mars Petcare), IDEXX Laboratories, Zoetis and Wisdom Panel (Mars Petcare). Embark Veterinary is listed as an emerging player. Direct peers are PetDx, Anivive Lifesciences, Torigen Pharmaceuticals, VetDC (now Elanco) and Ardent Animal Health.
Does FidoCure have an API?
No public API is recorded for FidoCure.
What industry is FidoCure in?
FidoCure's product category is Veterinary Precision Oncology. Its primary akta.pro industry code is HLAMADAE, Molecular & Genetic Testing (Breed, Hereditary Disease, Oncology), with a secondary code of HLAMADAJ, Oncology Diagnostics (Liquid/Tissue Biomarkers, Flow Cytometry). Its NAICS code is 621511 and its SIC code is 2835.